Iuliia Pilipenko

Iuliia Pilipenko

Auto-generated profile, based on publicly available information

Iuliia Pilipenko

School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2025 in Biomacromolecules
Verified
Journal Article
Closed access
IPIuliia Pilipenko
Iuliia Pilipenko
TSTeemu Sorsa
Teemu Sorsa
AVAnnika Valtari
Annika Valtari
SPSusanna Posio
Susanna Posio
KVKati-Sisko Vellonen
Kati-Sisko Vellonen
AUArto Urtti
Arto Urtti

12 December 2025 in Advanced Healthcare Materials
Verified
Journal Article
Open access
EGElizaveta Gusarova
Elizaveta Gusarova
FAFatemeh Ahmadi
Fatemeh Ahmadi
JCJennifer Cruickshank
Jennifer Cruickshank
ZMZheyuan Miao
Zheyuan Miao
MMMariia Moshkova
Mariia Moshkova
EKEugenia Kumacheva
Eugenia Kumacheva
Patient‐derived cancer organoids have emerged as a promising in vitro model for fundamental cancer research and drug screening for therapeutic cancer treatment. Yet, while the inherent acidification of the tumor environment in vivo is controlled at a particular level, hydrogel scaffolds used for organoid culture lack this ability and their pH falls outside the physiologically relevant range. The excessive acidification can also lead to the degradation of pH‐sensitive hydrogel scaffolds during long‐term organoid culture, thus changing the mechanical properties of the organoid microenvironment. Here, we report a biomimetic fibrous hydrogel with built‐in buffering capacity, which enables control of the local acidification of the organoid environment to maintain its mechanical and structural stability. The hydrogel is formed from aldehyde‐functionalized cellulose nanocrystals carrying histidine buffering molecules, and gelatin. During long‐term organoid culture, the hydrogel maintained the pH in the physiologically relevant range, while maintaining network integrity and mechanical properties. The organoids grown in this hydrogel exhibited enhanced proliferative activity of cancer cells, thus reflecting a more homeostatic tumor‐like niche. This work shows that introducing a buffering functionality into the hydrogel scaffold enables significantly improved support for long‐term culture of patient‐derived breast cancer organoids under physiologically relevant conditions.

30 June 2026 in Acta Biomaterialia
Verified
Journal Article
Open access
IPIuliia Pilipenko
Iuliia Pilipenko
KSKatja Stenberg
Katja Stenberg
JPJooseppi Puranen
Jooseppi Puranen
ETElisa Toropainen
Elisa Toropainen
IMIida Määttä
Iida Määttä
ASAstrid Subrizi
Astrid Subrizi
Therapeutic antibodies are a cornerstone of modern medicine, providing targeted and effective treatments for a wide range of diseases. Antibody delivery, however, has long been recognized as a major bottleneck for safety and efficacy. We developed a hyaluronic acid-poloxamer 407-calcium (HAP-Ca2+) thermoresponsive hydrogel for the controlled, long-term delivery of a full-length human monoclonal antibody (mAb) and an antibody fragment (Fab). The hydrogel enabled sustained, biphasic release of the mAb without initial burst (∼60% released over 25 days, followed by 20% over 35 days), while the Fab showed a modest burst (∼15% on day 1) and gradual release over two months. Both antibodies retained thermal stability and structural integrity, confirmed by nanoscale differential scanning fluorometry (nanoDSF) and circular dichroism (CD). Microscale thermophoresis (MST) showed maintained Fab binding over one month (KD ≈ 40 nM), while mAb EC50 increased from 0.108 nM to 0.338 nM. In vitro assays demonstrated biological activity for up to three weeks following hydrogel release. In vivo intravitreal administration in rabbits demonstrated that the hydrogel prolonged the vitreal half-life of mAb compared to PBS (7.0 ± 1.5 vs 5.1 ± 0.9 days), extending the time above estimated reference concentrations by approximately 5-11 days. Our results show that the HAP-Ca2+ thermoresponsive hydrogel can deliver Fab and mAb in a controlled, long-lasting manner while preserving their structure and activity, making it a strong candidate for sustained antibody delivery. More broadly, thermoresponsive hydrogels like this are emerging as powerful tools to enhance the safety and efficacy of antibody therapies. STATEMENT OF SIGNIFICANCE: Antibodies are among the most powerful medicines but delivering them safely and steadily remains a challenge. We designed a smart hydrogel that gradually releases both a full-length antibody and a smaller antibody fragment, avoiding sudden bursts that can cause side effects. Importantly, the antibodies retain their structure and activity for weeks after release. This represents an important step toward achieving controlled, long-term delivery for these complex molecules. More broadly, our study suggests that temperature-responsive hydrogels could serve as promising antibody delivery systems, an approach with the potential to make future therapies safer, longer-lasting, and more practical for real-world patient care.

3 August 2026 in International Journal of Pharmaceutics
Verified
Journal Article
Open access
TSTeemu Sorsa
Teemu Sorsa
IPIuliia Pilipenko
Iuliia Pilipenko
EVEetu Valkama
Eetu Valkama
HKHelena Kähärä
Helena Kähärä
MMMarcin Marczak
Marcin Marczak
ASAstrid Subrizi
Astrid Subrizi